Better pharmacotherapy for schizophrenia: What does the future hold?

Current Psychiatry Reports

Volumn 10, Issue 4, 2008, Pages 352-358

  Webber, Michael A ^b   Marder, Stephen R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [(2,4 DIMETHOXY)BENZYLIDENE]ANABASEINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACP 104; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLONIDINE; CLOZAPINE; CYCLOSERINE; DAR 0100; DEXTRO SERINE; DIHYDREXIDINE; DONEPEZIL; FLUVOXAMINE; GALANTAMINE; GLYCINE; GLYCINE REUPTAKE INHIBITOR; GUANFACINE; HALOPERIDOL; LY 2140023; MIRTAZAPINE; NEUROLEPTIC AGENT; NORCLOZAPINE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; RIVASTIGMINE; SARCOSINE; SELEGILINE;

ACADEMIC ACHIEVEMENT; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; FUNCTIONAL STATUS; HUMAN; HUMAN RELATION; HYPOTENSION; JOB PERFORMANCE; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN TARGETING; PSYCHOSIS; REMISSION; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE;

COGNITION DISORDERS; DRUG THERAPY; FORECASTING; HUMANS; SCHIZOPHRENIA;

EID: 48749123578     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-008-0056-8     Document Type: Review

References (50)

1. Hegarty JD, Baldessarini RJ, Tohen M, et at.: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994, 151:1409-1416.
2. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996, 153:321-330.
3. Stahl SM, Buckley PF: Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 2007, 115:4-11.
4. Carpenter WT: Clinical constructs and therapeutic discovery. Schizophr Res 2004, 72:69-73.
5. Davidson L, Schmutte T, Dinzeo T, et al.: Remission and recovery in schizophrenia: practitioner and patient perspectives. Schizophr Bull 2008, 34:5-8.
6. Bellack AS: Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull 2006, 32:432-442.
7. Brekke JS, Maanse H, Long J, Green MF: How neurocognitive and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull 2007, 33:1247-1256.
8. McGurk SR, Mueser KT, Feldman K, et al.: Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. Am J Psychiatry 2007, 164:437-441.
9. Peer JE, Spaulding WD: Heterogeneity in recovery of psychosocial functioning during psychiatric rehabilitation: an exploratory study using latent growth mixture modeling. Schizophr Res 2007, 93:186-193.
10. McEvoy JP, Lieberman JA, Stroup TS, et al.: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163:600-610.
11. Sur C, Mallorga PJ, Wittmann M, et al.: N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 2003, 100:13674-13679.
12. Shim SS, Hammonds MD, Kee BS: Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008, 258:16-27.
13. Javitt DC, Duncan L, Balla A, Sershen H: Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 2005, 10:276-286.
14. Evins AE, Fitzgerald SM, Wine L, et at.: Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000, 157:826-828.
15. Goff DC, Tsai G, Manoach DS, et al.: D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996, 153:1628-1630.
16. Shaw P, Sporn A, Gogtay N, et al.: Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006, 63:721-730.
17. Lameh J, Burstein ES, Taylor E, et al.: Pharmacology of N-desmethylclozapine. Pharmacol Ther 2007, 115:223-231.
18. Natesan S, Reckless GE, Barlow KB, et al.: Evaluation of N-desmethylclozapine as a potential antipsychotic-preclinical studies. Neuropsychopharmacology 2007, 32:1540-1549.
19. Buchanan RW: Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007, 33:1013-1022.
20. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR: The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32:214-219.
21. Berk M, Ichim C, Brook S: Efficacy of mirtazapine add-on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind, randomized, placebo-controlled study. Int Clin Psychopharmacol 2001, 16:87-92.
22. Jockers-Scherubl MC, Bauer A, Godemann F, et al.: Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2005, 20:27-31.
23. Silver H, Aharon N, Kaplan A: Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms. Schizophr Bull 2003, 29:541-546.
24. Bodkin JA, Siris SG, Bermanzohn PC, et al.: Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 2005, 162:388-390.
25. Amiri A, Noorbala AA, Nejatisafa AA, et al.: Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum Psychopharmacol 2008, 23:79-86.
26. Heresco-Levy U, Javitt DC, Ermilov M, et al.: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999, 56:29-36.
27. Heresco-Levy U, Javitt DC: Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 2004, 66:89-96.
28. Buchanan RW, Javitt DC, Marder SR, et al.: The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007, 164:1593-1602.
29. Patil ST, Zhang L, Martenyi F, et al.: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007, 13:1102-1107.
30. Nuechterlein KH, Batch DM, Gold JM, et al.: Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004, 72:29-39.
31. Marder SR, Fenton W: Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004, 72:5-9.
32. Green MF: Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol 2007, 3:159-180.
33. Gray JA, Roth BL: Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007, 33:1100-1119.
34. Buchanan RW, Freedman R, Javitt DC, et al.: Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007, 33:1120-1130.
35. Olincy A, Harris JG, Johnson LL, et al.: Proof-of-concept trial of an alpha-7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006, 63:630-638.
36. Keefe RS, Malhotra AK, Meltzer HY, et al.: Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008, 33:1217-1228.
37. Sharma T, Reed C, Aasen I, Kumari V: Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006, 85:73-83.
38. Buchanan RW, Conley RR, Dickinson D, et al.: Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008, 165:82-89.
39. Raedler TJ, Bymaster FP, Tandon R, et al.: Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007, 12:232-246.
40. Li Z, Huang M, Ichikawa J, et al.: N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 2005, 30:1986-1995.
41. George MS, Molnar CE, Grenesko, EL, et al.: A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 2007, 93:42-50.
42. Mu Q, Johnson K, Morgan PS, et al.: A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 2007, 94:332-341.
43. Goff DC, Leahy L, Berman I, et al.: A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001, 21:484-487.
44. Goff DC, Lamberti JS, Leon AC, et al.: A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008, 33:465-472.
45. Tsai G, Yang P, Chung LC, et al.: D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998, 44:1081-1089.
46. Friedman JI, Temporini H, Davis KL: Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999, 45:1-16.
47. Fields RB, Van Kammen DP, Peters JL, et al.: Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings. Schizophr Res 1988, 1:417-423.
48. Friedman JI, Adler DN, Temporini H, et al.: Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001, 25:402-409.
49. Lewis DA, Hashimoto T, Volk DW: Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005, 6:312-324.
50. Lewis DA, Moghaddam B: Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 2006, 63:1372-1376.